AGENUS INC (AGEN) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 42 days, typically, give or take 15 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q1 FY2026Mon, May 11, 2026before open 41 8-K
Q4 FY2025Mon, Mar 16, 2026before open 75 8-K
Q3 FY2025Mon, Nov 10, 2025before open 41 8-K
Q2 FY2025Mon, Aug 11, 2025before open 42 8-K
Q1 FY2025Mon, May 12, 2025before open 42 8-K
Q4 FY2024Tue, Mar 11, 2025before open 70 8-K

What they guided beta

Q3 FY2026 "Based on the current operating plan, the upfront proceeds are expected to support ROBBIN initiation, regulatory activities and operations through the third quarter of 2027." exhibit
Q3 FY2026 "Assuming full exercise of the warrants, the financing is expected to support the planned ROBBIN program and company operations through year-end 2031." exhibit
Q3 FY2026 "Based on the current operating plan, the upfront proceeds are expected to support ROBBIN initiation, regulatory activities and operations through the third quarter of 2027." exhibit
Q3 FY2026 "Assuming full exercise of the warrants, the financing is expected to support the planned ROBBIN program and company operations through year-end 2031." exhibit
Q3 FY2026 "2027: Additional clinical publications and updates as available, and potential additional regulatory submissions About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents." exhibit
Q2 FY2026 "ROBBIN addresses approximately 38,000 newly diagnosed U.S. patients annually and an estimated annual U.S. sales opportunity of more than $7 billion; initiation and first patient dosing are expected in the first quarter of 2027" exhibit
Q2 FY2026 "Based on the company’s current operating plan, the upfront proceeds are expected to support ROBBIN initiation, regulatory alignment and company operations through Q3 2027." exhibit
Q2 FY2026 "Assuming full exercise of the warrants, the financing is expected to support the planned ROBBIN program and company operations through year-end 2031." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AGEN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AGEN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

AGEN earnings date badge

HTML

<a href="https://veritasdata.dev/company/AGEN/"><img src="https://veritasdata.dev/embed/AGEN.svg" alt="AGEN earnings date" width="240" height="56"></a>

Markdown

[![AGEN earnings date](https://veritasdata.dev/embed/AGEN.svg)](https://veritasdata.dev/company/AGEN/)

Script

<script async src="https://veritasdata.dev/embed/AGEN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AGEN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.